Pay in 4 interest-free payments of $5.04 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Insert needle straight into muscle at a 90-degree angle
LF has designed the Treatment Tables to enhance the comprehension and comparability of various Lipedema treatments utilized by patients and clinicians
discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data
It has demonstrated positive treatment outcomes for GI tract issues, periodontitis, and lesions of the liver and pancreas
US$ 25.32
US$ 22.64
US$ 28.60
US$ 22.41
US$ 22.84
US$ 20.60
US$ 24.95
US$ 22.57
US$ 24.73
US$ 25.12
